An observational study in Congenital Heart Disease, Aortic Valve Stenosis and Fetal Cardiac Disorder, sponsored by Queen Silvia Children's Hospital, Gothenburg, Sweden. Recruiting at 13 sites in 8 countries. Open to participants aged 23 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by Queen Silvia Children's Hospital, Gothenburg, Sweden · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective.
The aim of this study is: 1/ to evaluate whether balloon dilation during the fetal period of a narrowed aortic valve can reduce the risk of the left ventricle becoming underdeveloped and the baby being born with a so-called univentricular heart (HLHS); 2/ to investigate whether such treatment improves the prognosis for this group of children with a very complex and severe heart defect and 3/ to also describe side effects and risks in fetuses and mothers of the fetal procedure.
Routinely collected pre- and postnatal clinical data will be entered into a digital database and echocardiographic examinations will be uploaded to a server. A core lab will measure and analyze all echocardiographic examinations according to protocol. The growth of the left heart structures and the postnatal outcome will be compared between the intervention and non-intervention groups.
The decision whether a fetal balloon dilatation shall be attempted is not part of the study protocol. The number of examinations of mother/fetus/infant in this study is not different from the number of examinations that will be recommended for someone choosing not to be part of this study. Participation in the study does not affect the care and treatment mothers and fetuses are receiving during pregnancy, nor how the infant is examined and treated after birth.
67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 23 observational studies indexed under Hypoplastic Left Heart Syndrome.
Browse Hypoplastic Left Heart Syndrome studies →This is the only study on the registry with Queen Silvia Children's Hospital, Gothenburg, Sweden as lead sponsor.
Compared within Hypoplastic Left Heart Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Defects, Congenital. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study population consists of fetuses and children with aortic valve stenosis and/or hypoplastic left heart syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A. All of the following echocardiographic criteria need to be satisfied between 23+0 and 31+6 weeks (z-scores according to Schneider et al):
Left ventricular inlet length in diastole :
B. All of the following postnatal treatment options need to be available: 1. Surgical or catheter based aortic valvotomy 2. Ross-Konno surgery 3. Norwood or hybrid stage-one surgery
Exclusion Criteria:
Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria
Procedure: Fetal aortic balloon dilatation
Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria which are identical with the criteria in the Fetal intervention group
Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
Transplantation-free survival
Transplantation-free survival from fetal diagnosis to 2 years postnatal age with a biventricular circulation without pulmonary hypertension at that time. Absence of pulmonary hypertension is defined as a TR max velocity ≤ 2.8 m/s with no other echocardiographic signs of pulmonary hypertension and/or catheter data showing a mean pulmonary arterial pressure \<25 mmHg.
Time frame: Follow-up from study inclusion during fetal life until 2 years postnatal age
Intervention-related fetal death
Intervention-related fetal death (defined as fetal death within 24 hours of procedure)
Time frame: From the time of fetal intervention until 24 hours after the intervention
Fetal death not directly related to the intervention
Fetal death not directly related to the intervention, except termination of pregnancy
Time frame: From 24 hours after fetal intervention until fetal death, up to 20 weeks after study inclusion.
Maternal complications to fetal intervention procedure
Maternal complications to procedure requiring intensive care or resulting in maternal death
Time frame: From time of fetal intervention until 24 hours after the intervention
Preterm delivery
Preterm delivery before 37 weeks gestational age
Time frame: From time of fetal intervention until 37 weeks gestational age, maximum 14 weeks
Fetal left heart growth
Fetal left heart growth as measured with dimensions expressed a z-scores of the mitral valve diameter, left ventricular inlet length and aortic valve diameter
Time frame: From the date of study inclusion until just before the first postnatal catheter or surgical intervention, or death, whichever comes first, total time frame 7 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Dec 2029, 107 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypoplastic Left Heart Syndrome →